Siemens Healthineers has received FDA approvals for its AI imaging technology, but faces challenges in its diagnostics division.
Siemens Healthineers recently achieved six regulatory approvals for its Artis interventional imaging portfolio, marking a significant advancement for its Optiq AI imaging chain, which enhances image quality using deep learning. However, this positive development contrasts sharply with the ongoing struggles in its diagnostics unit, which experienced a 6.5% revenue decline and a drastic drop in operating margins to 0.9%. In light of these issues, the company has revised its revenue growth outlook for 2026 downward.
Despite the imaging segment's growth of 6.1% and Varian's 7.5% increase in cancer therapy revenue, investor sentiment remains cautious. Siemens Healthineers' stock has seen a steep decline of over 22% year-to-date, and analysts are divided on its future. While Deutsche Bank and Jefferies have adjusted their price targets downward, JPMorgan maintains a more optimistic view, reflecting the uncertainty surrounding the company's strategic overhaul and diagnostics recovery.
In response to these challenges, Siemens is initiating a spin-off of its diagnostics unit, planning to reduce its ownership significantly. This move aims to streamline operations and alleviate financial burdens associated with substantial loans. Additionally, the company is refreshing its leadership with the appointment of Martin Stumpe as the new chief technology officer, indicating a commitment to advancing AI in healthcare. As Siemens embarks on this transformative journey, the coming weeks will be critical in determining its path forward and restoring investor confidence.